Teva Pharmaceutical Industries Ltd (TEVA.TA) (TEVA.O) plans to acquire specialty drugmaker Cephalon (CEPH.O) for $81.50 a share, topping an unsolicited bid by Canada's Valeant Pharmaceuticals International Inc (VRX.TO). Teva said the deal was worth about $6.8 billion on an enterprise basis. The deal is worth about $6.2 billion, based on the number of Cephalon shares outstanding, according to Thomson Reuters data.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. Shares of TEVA remained unchanged at $45.73. In the past year, the shares have traded as low as $44.86 and as high as $60.78. On average, 7662090 shares of TEVA exchange hands on a given day and today's volume is recorded at 1000.
Cephalon, Inc. is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Shares of CEPH remained unchanged at $77.02. In the past year, the shares have traded as low as $54.15 and as high as $77.59. On average, 2796530 shares of CEPH exchange hands on a given day and today's volume is recorded at 5285.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $52.63. In the past year, the shares have traded as low as $13.67 and as high as $55.00. On average, 2715770 shares of VRX exchange hands on a given day and today's volume is recorded at 3365.
Source
